Category Archives: Psoriasis

The diagnosis and treatment of skin conditions such as eczema, psoriasis and skin cancer could be improved by using T-rays to analyse the structure of skin.

This is the claim of scientists from Warwick University and The Chinese University of Hong Kong (CUHK) who have built a more detailed picture of the skins structure and hydration levels by analysing T-rays fired from several different angles.

Warwick leads breakthrough in terahertz imaging

Their method, detailed inAdvanced Photonics Research, could provide a new tool for scientists and clinicians for characterising the properties of skin in individuals.

Sitting between infrared and WiFi on the electromagnetic spectrum, T-rays (Terahertz (THz)) radiation sees through plastics, ceramics and clothes. They are non-ionising also, so safe for use in biological settings.

Only the T-rays passing through the outer layers of skin (stratum corneum and epidermis) before being reflected back can be detected, making T-ray imaging a potentially effective way of monitoring these outermost layers. The University said that to test this, terahertz light is focused onto the skin via a prism to align the ray in a particular focal plane. Depending on the properties of the skin, that light will be reflected back slightly differently. Scientists can then compare the properties of the light before and after it enters the skin.

Limitations in standard THz reflection spectroscopy were overcome by using ellipsometry, which involves focusing T-rays at multiple angles on the same area of skin.

By using ellipsometry they could accurately calculate the refractive index of skin measured in two directions at right angles to each other. The difference between these refractive indices is termed birefringence and the research marks the first time that the THz birefringence of human skin has been measuredin vivo.

Professor Emma Pickwell-MacPherson, from the Department of Physics at Warwick University and the Department of Electronic Engineering at CUHK, said: We wanted to show that we could doin-vivoellipsometry measurements in human skin and calculate the properties of skin accurately. In ordinary terahertz reflection imaging, you have thickness and refractive index combined as one parameter. By taking measurements at multiple angles you can separate the two.

Hydrated skin will have a different refractive index from dehydrated skin. For people with skin disorders, well be able to probe the hydration of their skin quantitatively, more so than existing techniques. If youre trying to improve skincare products for people with conditions like eczema or psoriasis, we would be potentially be able to make quantitative assessments of how the skin is improving with different products or to differentiate types of skin.

For skin cancer patients, you could also use THz imaging to probe the skin before surgery is started, to get a better idea of how far a tumour has spread. Skin cancer affects the properties of the skin and some of those are unseen as theyre beneath the surface.

To test their method, volunteers placed their arm on the imaging window of their T-ray equipment for 30 minutes, after acclimatising to the ambient temperature and dryness of the laboratory. By holding their skin against the surface of the imaging window, they blocked water from escaping from their skin as perspiration, a process called occlusion.

The researchers then made four measurements at right angles to each other every two minutes over half an hour, so they could monitor the effect of occlusion. Because T-rays are particularly sensitive to water, they could see a noticeable difference as water accumulated in the skin, suggesting that the method could show how effective a product is at keeping skin hydrated.

Further research will look at improving the instrumentation of the process and how it might work as a practical device.

View original post here:
T-rays help to characterise psoriasis and skin cancer - The Engineer

To our knowledge, this study is the first to assess the rate of any type of psoriasis flare during or immediately following the administration of systemic corticosteroids in patients with a known history of psoriasis.To determine the rates and types of psoriasis flares during or within 3 months after concluding systemic corticosteroid administration in adult patients with a known history of psoriasis.This retrospective cohort study assessed adult patients (18 years at the time of psoriasis diagnosis) evaluated in the Marshfield Clinic Health System (Marshfield, Wisconsin) with an established diagnosis of psoriasis and exposure to at least 1 systemic corticosteroid from October 31, 2012, to July 1, 2018. Exclusion criteria were patients younger than 18 years, patients with a diagnosis of psoriatic arthritis, and patients receiving only topical, intraarticular, or intrabursal corticosteroids.The primary outcome was rate of psoriasis flares during or within 3 months of discontinuation of the patients first course of systemic corticosteroids. Secondary measures included rates of specific types of psoriasis flares, including pustular, erythrodermic, and worsening plaque stage psoriasis.Of 516 cohort patients, 288 (55.8%) were women, and the mean (SD) age at first psoriasis diagnosis was 49.6 (17.0) years. Among 1970 patients with a diagnosis of psoriasis before receiving systemic corticosteroids, a 1.42% (95% CI, 0.72%-2.44%) psoriasis flare rate of any type was identified when prescribed their first course of systemic corticosteroids. Further stratification identified only 1 severe flare (erythroderma) among all flares reported, with no pustular psoriasis flares identified (0.07%; 95% CI, 0.00%-0.26%).In this study, the rates of psoriasis flares were low, especially for severe psoriasis flares. Our results suggest that systemic steroids may be much less likely to trigger severe flares in patients with psoriasis than what is traditionally taught in dermatology.

PubMed

View post:
Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of Psoriasis. - Physician's Weekly

Dermatologic conditions are routinely overlooked and misdiagnosed in people of color. The COVID-19 pandemic provides another notice of why dermatology training needs urgent updating.

During a recent Ethics Talk videocast from the AMA Journal of Ethics (@JournalofEthics), Jenna Lester, MD, assistant professor of dermatology at the University of California, San Francisco, School of Medicine talked about why COVID toes should bring physicians attention to long-standing health inequities.

Accounting for differences

The most well-known dermatologic manifestation of COVID-19 is COVID toes, a purplish-red discoloration of the tops and tips of the toes. There are other cutaneous manifestations, such as papulosquamouseruptions, pityriasis rosea-like eruptions and more vasculitic-type lesions.

"A lot of these have a basis of inflammation, and inflammation appears differently in different tones of skin, Dr. Lester said. So what may look red or pink in someone with light skin may actually look purple to blue, or darkerdark brown evenin someone with darker skin. So if your eye is not trained to recognize these things in different skin tones, it might be quite easy to miss it.

The good news

If properly trained, however, physicians can help patients keep an eye out for skin signs of COVID-19 infection.

One of the great things about the skin is that it's an external organ that patients can look at with us, she said. So if doctors, and then subsequently patients, are aware of the manifestations in all different skin tones we might be able to say, If you notice something like this on your skin, this could be an early sign of COVID-19. You should consider sheltering in place, self isolating, getting testing if you can.

Check out how to tackle health inequities with science, data during pandemic.

Whats in the way

The problem is that most physicians are not, in fact, trained to recognize dermatologic conditions in varying skin tones, Dr. Lester said. Most of the photos in medical education textbooks, for example, show white patients.

We need to think about increasing representation in our photographs in dermatology specifically, she said, adding that terminology is important too. So we're not saying the salmon pink patches of psoriasis are classic presentations of psoriasis, because psoriasis in someone with dark skin does not look like that.

But there are also systemic forces in play, Dr. Lester noted. Economics, for example, plays a role in patient access: Dermatology is a lucrative specialty, and many dermatologists do not accept Medicaid.

Dr. Lester started a skin-of-color clinic at UCS, that provides high-quality dermatologic care for Black, Latino, Asian, Native Indian and Pacific Islander communities.

Theres research that suggests that patients of color, particularly Black patients, appreciate having a dermatology space that is built for them. They feel better getting care in a skin of color clinic than in a general dermatology clinic, she said. My ultimate goal would be that these clinics don't have to exist, that we're able to provide this same type of care where patients feel as comfortable in any dermatology setting. For now, I think it's important to create a place where these patients feel comfortable coming and returning to.

For a model like this to work at a wider level, though, the system itself needs to change, Dr. Lester noted.

We know that there are fewer Black men in medical school now than there were in the 70s, she said. So how can we, as a profession, diversify the people who make up our professionthat we have a diversity of thoughts and ideas and approaches to problems and solutions, as well? I really think that that is central to solving a lot of these issues.

Check outprevious episodesof the Ethics Talk podcast or subscribe to the series iniTunesor other services.

View post:
Dermatology a bellwether of health inequities during COVID-19 - American Medical Association

This report gives a vital investigation of the Global Plaque Psoriasis Treatment market and the development gauges for the conjecture time frame. This report likewise gives market estimating and figures to the Global Plaque Psoriasis Treatment market.

Some of the players in Plaque Psoriasis Treatment Market are Novartis AG (Switzerland),AbbVie Inc.(U.S),Amgen, Inc. (U.S),Johnson & Johnson (U.S),Eli Lilly and Company (U.S),Celgene Corporation (U.S),Sun Pharmaceuticals Industries Ltd. (India)

Request free sample copy of this https://www.precisionbusinessinsights.com/request-sample?product_id=23496

The most recent market report on Plaque Psoriasis Treatment industry offers a top to bottom investigation of this business vertical including key data concerning industry expectations, transcendently showcase inclinations, advertise size, piece of the overall industry, present valuation, and benefits estimations for the gauge time frame. The concise data in regards to the business additionally breaks down and clarifies the Plaque Psoriasis Treatment market development rate in the conjecture course of events, prompted by specific impetuses, a substance of which has been given in this exploration report related to the essential difficulties and development prospects present in the business.

Statistical surveying Place has included a report, Global Plaque Psoriasis Treatment Market Research Report 2020-2026 incorporates a careful investigation of the Plaque Psoriasis Treatment advertise in the anticipated period. Worldwide Plaque Psoriasis Treatment market report offers the most recent industry patterns, mechanical developments and figure showcase information. A profound jump perspective on Plaque Psoriasis Treatment industry dependent on market size, Plaque Psoriasis Treatment development, advancement plans, and openings is offered by this report. The estimate advertises data, SWOT examination, Plaque Psoriasis Treatment hindrances, and attainability study are the fundamental angles broke down in this report.

Request Customization at https://www.precisionbusinessinsights.com/request-customisation?product_id=23496

Key Features of the Report:

There are 10 Chapters to deeply display the Plaque Psoriasis Treatment market.Chapter 1 to analyze the top manufacturers of Plaque Psoriasis Treatment, with sales, revenue and price of Plaque Psoriasis Treatment in 2020 and 2026.

Chapter 2, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2020 and 2026.

Chapter 3, to show the global market by regions, with sales, revenue and market share of Plaque Psoriasis Treatment, for each region, from 2020 and 2026.

Chapter 4, 5, 6 and 7 to analyze the key regions, with sales, revenue and market share by key countries in these regions.

Chapter 8 and 9, to show the market by type and application, with sales market share and growth rate by type, application, from 2020 and 2026.

Chapter 10 Plaque Psoriasis Treatment market forecast, by regions, type and application, with sales and revenue, from 2020 and 2026.

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our Plaque Psoriasis Treatment is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

Go here to read the rest:
Plaque Psoriasis Treatment Market to receive overwhelming hike in Revenues by 2026 - Cheshire Media

Fort Collins, Colorado The Psoriasis Treatment Market 2020 Research Report provides information on the market size, share, trends, growth, competitive landscape, challenges and opportunities, revenue, and forecast to 2027. Reports Globe recently incorporated a comprehensive overview of the Psoriasis Treatment market into its extensive database. The Psoriasis Treatment Market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.

This innovative report uses SWOT, PESTLE, and Porters Five Forces analysis to get a deeper look at the Psoriasis Treatment market.

Download Exclusive Sample PDF along with few company profiles @ https://reportsglobe.com/download-sample/?rid=65209

The Major Players Profiled in this Report include

Impact of Covid-19 on this Market:

The coronavirus pandemic (COVID-19) has affected all aspects of life around the world. The study provides a comprehensive overview of the impact of the COVID-19 pandemic on the Psoriasis Treatment market and its key segments. It also covers the current and future impact of the pandemic and offers a post-COVID-19 scenario to provide a deeper understanding of the dynamic changes in market trends and scenarios.

Competitive Landscape:

Competitive Analysis is one of the best sections of the report, comparing the progress of leading companies using key metrics like market share, new developments, global reach, local competition, pricing, and production. . From the nature of the competition to future changes in the vendor landscape, the report offers an in-depth competitive analysis in the global Psoriasis Treatment Market.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=65209

Market Segments and Sub-segments Covered in the Report are as per below:

Psoriasis Treatment Market Segmentation, By Type

Psoriasis Treatment Market Segmentation, By Applications

Research Methodology:

Reports Globe follows a comprehensive research methodology to provide the most accurate market analysis. The company relies on a data triangulation model that can be used to assess market dynamics and provide accurate estimates. Key elements of the research methodology used for all of our market reports include:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=65209

In addition, Reports Globe has access to a wide range of reputable regional and global paid databases that help the company understand regional and global market trends and dynamics. The company analyzes the industry from a 360-degree perspective, i.e. H. From the supply and demand side, which allows us to provide detailed information about the entire ecosystem for each study. Finally, a top-down and bottom-up approach is taken to get the final search results.

It includes analysis on the following

Finally, the Psoriasis Treatment Market Report is a credible source of market research that will accelerate your business exponentially. The report gives the most important regional framework conditions, economic situations with item value, advantage, limit, production, supply, demand, market development rate and number, etc. Psoriasis Treatment Industry Report Also includes a new SWOT review task, speculative test research, and corporate return on investment research.

To learn more about the report, visit @ https://reportsglobe.com/product/global-psoriasis-treatment-assessment/

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Original post:
Psoriasis Treatment Market To Observe Exponential Growth By 2020-2027 | Reports Globe - Cheshire Media

Psoriasis Treatment Marketresearch report is the new statistical data source added byA2Z Market Research.

Psoriasis Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Psoriasis Treatment Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=280493

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Sun Pharmaceutical Industries Ltd., Amgen Inc., Novartis AG, LEO Pharma A/S, Eli Lilly and Company, UCB S.A., Johnson and Johnson Services, Inc., CELGENE CORPORATION, Pfizer Inc.,, AbbVie Inc., Merck and Co., Inc..

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Psoriasis Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Psoriasis Treatment markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=280493

Global Psoriasis Treatment Market Segmentation:

Market Segmentation: By Type

TNF InhibitorsInterleukinsOthers

Market Segmentation: By Application

Hospital PharmaciesRetail PharmaciesOnline pharmacies

Regions Covered in the Global Psoriasis Treatment Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Psoriasis Treatment Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Psoriasis Treatment market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Psoriasis Treatment market.

Table of Contents

Global Psoriasis Treatment Market Research Report 2020 2026

Chapter 1 Psoriasis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Psoriasis Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=280493

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See the rest here:
Impact of COVID-19 on Psoriasis Treatment Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Sun Pharmaceutical Industries...

The Chronic Plaque Psoriasis Therapeutics Market grew in 2019, as compared to 2018, according to our report, Chronic Plaque Psoriasis Therapeutics Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Chronic Plaque Psoriasis Therapeutics Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Chronic Plaque Psoriasis Therapeutics Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-chronic-plaque-psoriasis-therapeutics-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Chronic Plaque Psoriasis Therapeutics Market is analysed based on product types, major applications and key players

Key product type:ClinicalNon-ClinicalInactive

Key applications:HospitalsAmbulatory Surgical CentersOthers

Key players or companies covered are:AbbvieNovartis InternationalPfizerMerckAstelllas PharmaGlaxoSmithKline

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-chronic-plaque-psoriasis-therapeutics-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Chronic Plaque Psoriasis Therapeutics Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Chronic Plaque Psoriasis Therapeutics Market?4. What is the likely market forecast & how will be Chronic Plaque Psoriasis Therapeutics Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Chronic Plaque Psoriasis Therapeutics Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

Visit link:
Chronic Plaque Psoriasis Therapeutics Market Research Report: Industrial Chain, Sourcing Strategy and Downstream Buyers with Forecast 2026 - The...

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that SULINNO (adalimumab injection), a recombinant human anti-TNF- monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of polyarticular juvenile idiopathic arthritis (pJIA), which is the fourth approved indication of SULINNO in China. On September 2, 2020, SULINNO was approved by NMPA for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis.

Juvenile idiopathic arthritis (JIA) is defined as arthritis with an unknown cause lasting at least 6 weeks in children aged 16 years or younger. Arthritis is divided into oligarthritis <5 jointsand polyarthritis. Polyarthritis can be further divided into rheumatoid factor (RF)-negative polyarthritis and RF-positive polyarthritis. It is estimated RF-negative polyarticular JIA affects 1 to 4 per 100,000 children annually. Less commonly, RF-positive polyarticular JIA occurs in an estimated 0.3 to 0.7 per 100,000 children each year. JIA occurs in children at a young age, and is often accompanied by many complications that will lead to high rates of defects, disability and mortality when left untreated, deeply impacting the quality of life in children. Early aggressive therapy leads to improved outcomes and prevents potential disease complications.

Since the launch of adalimumab, it has been approved worldwide for the treatment of seventeen diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriasis arthritis, juvenile idiopathic arthritis, crohn's disease (including pediatric crohn's disease), ulcerative colitis, hidradenitis suppurativa, uveitis, etc. The efficacy and safety of adalimumab has been well recognized globally, and adalimumab injection is widely used in the North America and Europe. It has been consistently recommended in multiple diagnostic and therapeutic guidelines for the treatment of these diseases, and its significant efficacy has been universally recognized. SULINNO is adalimumab biosimilar developed by Innovent, and its clinical results were published in the Inaugural Issue of The Lancet Rheumatology in 2019. The launch of SULINNO has provided more Chinese patients with high-quality and relatively affordable adalimumab injection, bringing hope and opportunities to more patients.

Dr. Qian Lei, Senior Director of Medical Sciences and Strategies of Special Diseases of Innovent, stated: "Not only does Juvenile idiopathic arthritic lead to functional impairment and decrease in quality of life and social participation in children, but also places a huge economic burden on their families. The approval of SULINNO will provide a high-quality and accessible treatment option for children with polyarticular idiopathic arthritis in China. We hope that this product will benefit more children with polyarticular idiopathic arthritis and their families, allowing them to receive early treatment with high-quality biological drugs.''

About SULINNO

SULINNO is an adalimumab (Humira) biosimilar and a recombinant human anti-TNF- monoclonal antibody independently developed by Innovent. TNF is a proinflammatory cytokine mainly produced by activated macrophages, natural killer cells and T lymphocytes, which is involved in inflammatory and immune responses. Anti-TNF- antibody can bind to human TNF- monomer or trimer, block TNF- binding to the cellular surface receptor, p55 and p75, and neutralize the cytotoxic effect of TNF-, thereby inhibiting the release of TNF- mediated inflammatory factors and cytokines, the adhesion and infiltration of inflammatory cells, the proliferation of fibroblasts and the activation of osteoclasts.

The results of a complete pre-clinical comparison showed that SULINNO has similar in vitro biological activity (binding activity to target antigen TNF- and neutralizing activity), physicochemical property and pharmacokinetic characteristics to those of Humira. The similarities were also demonstrated in pharmacological and toxicological studies. The head-to-head clinical study comparing SULINNO and Humira conducted in patients with ankylosing spondylitis demonstrated a clinical similarity. The study results were published at Inaugural Issue of The Lancet Rheumatology in 2019.

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT (sintilimab injection), BYVASDA (bevacizumab biosimilar) , SULINNO (adalimumab biosomilar) and HALPRYZA(rituximab biosimilar)on market, 4 assets in Phase III or pivotal clinical trials, and additional 15 molecules in clinical trials. TYVYT (sintilimab injection) has been the only PD-1 inhibitor included in the NRDL since 2019.

Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic collaborations with Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with all relevant parties to help advance China's biopharmaceutical industry, improve drug availability to ordinary people and enhance the quality of the patients' lives. For more information, please visit: http://www.innoventbio.com.

View original content:http://www.prnewswire.com/news-releases/innovent-announces-nmpa-granted-new-indication-approval-for-sulinno-adalimumab-injection-in-china-for-the-treatment-of-polyarticular-juvenile-idiopathic-arthritis-301178781.html

SOURCE Innovent Biologics

Company Codes: HongKong:1801, OTC-PINK:IVBIY

The rest is here:
Innovent Announces NMPA Granted New Indication Approval for SULINNO (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile...

This article was originally published here

Expert Opin Biol Ther. 2020 Nov 20. doi: 10.1080/14712598.2021.1853698. Online ahead of print.

ABSTRACT

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged 18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen cytokine storm of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

PMID:33216643 | DOI:10.1080/14712598.2021.1853698

Read more:
Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID...

EXTON, Pa., Nov. 17, 2020 /PRNewswire/ --The 2020 audit included in Spherix's RealWorld Dynamix: Biologic/Small Molecule Switching in Psoriasis (US) service focuses on a critical facet of overall therapy prescribing for plaque psoriasis (PSO) patients advanced therapy switching. The study captures the myriad of data surrounding the process by which PSO patients are switched from one biologic/small molecule agent to another.

Since the introduction of AbbVie's Skyrizi in April 2019, switch-to share for the IL-23 inhibitor class has nearly tripled. The newest market entrant now garners the greatest switch-to rate among all commercial biologics in PSO and has made great strides in the second- and third-line setting compared to 2019.

Which brands are taking the biggest hit? Two biologics in particular who once held their position as leaders in the market year over year, Novartis' Cosentyx and AbbVie's Humira, have seen consecutive declines in switch-to share since the introduction of Skyrizi.

However, the AbbVie portfolio remains strong, as patients who were switched to Skyrizi often switched from sister brand Humira offsetting any deficits the TNF inhibitor experienced. Of note, the percent of current Skyrizi patients being switched from Amgen's Otezla (a commonly used first-line agent in addition to the TNF inhibitors) has substantially increased from the prior year. This, coupled with the fact that switches from IL-17 inhibitors (which are more commonly used in later lines of therapy) are decreasing, suggests that Skyrizi is being prescribed earlier in the treatment algorithm.

The Spherix study, which assesses reasons behind prescribing behavior, found that efficacy in both skin and joints remains a top reason for current brand selection in PSO, highlighting the importance of treating psoriatic disease. Although IL-17 inhibitors are prescribed more often than IL-23 inhibitors when joint involvement is a factor, the IL-23 class is gaining momentum. In July 2020, Janssen's Tremfya became the first IL-23 inhibitor to gain FDA approval for the treatment of moderate to severe psoriatic arthritic (PsA).

Indeed, nearly one-third of Tremfya patients included in the study present with any joint symptoms, a figure that is not far off from the rates seen in patients being treated with IL-17 inhibitors. The audit also found that considerably more PSO patients overall present with mild joint involvement than moderate to severe indicating the "mild PsA" patient segment in PSO presents a greater opportunity for brands to capture more share.

When examining the switch-to brand based on the severity of joint involvement, the IL-23 inhibitors are being prescribed more often for patients with concomitant mild PsA than moderate to severe and that number has grown since the prior year. On the other hand, slightly less PSO patients with mild joint involvement were switched to an IL-17 inhibitor, and that figure has declined year over year.

As the PSO market is expected to further expand in 2021 with UCB's bimekizumab, a dual IL-17A and IL-17F inhibitor, switching market dynamics are likely to continue shifting. In fact, the majority of PSO patients are considered potential candidates for bimekizumab (pending approval) should their current switch-to agent deem unsuccessful followed by Eli Lilly's pipeline IL-23 inhibitor, mirikizumab.

Patients currently prescribed TNF and IL-17 inhibitors are more likely to be considered for bimekizumab than patients being treated with other mechanisms of action. Interestingly, patients currently on an IL-23 inhibitor are more likely to be considered for mirikizumab, while current Otezla patients are more likely to be considered for other oral agents, such as BMS' TYK2 inhibitor, deucravacitinib highlighting further in-class competition in the PSO switch market.

About RealWorld DynamixRealWorld Dynamix: Biologic/Small Molecule Switching in Psoriasis (US) is an independent, data-driven service unmasking real patient management patterns through annual reports based on chart audits of ~1,000 patients. The report uncovers the "why" behind treatment decisions, includes year over year trending to quantify key aspects of market evolution, and integrates specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns.

About Spherix Global InsightsSpherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:Kristen Henn, Business Development ManagerEmail:[emailprotected]www.spherixglobalinsights.com

SOURCE Spherix Global Insights

Home

Original post:
IL-23 Inhibitors Take Over the US Psoriasis Switching Market at the Expense of the IL-17 and TNF Inhibitors - PRNewswire